KZR — Kezar Life Sciences Share News
0.000.00%
Last trade - 00:00U.S. RESEARCH ROUNDUP-Beacon Roofing Supply, Bioxcel Therapeutics, Cambium Networks
Kezar Life Sciences rises on strategic restructuring to extend financial runway
Brief: Kezar Life Sciences And Everest Medicines Enter Into An Agreement To Develop And Commercialize Zetomipzomib For Lupus Nephritis And Other Potential Indications In Greater China, South Korea And Southeast Asia
Kezar Life Sciences Inc reports results for the quarter ended in June - Earnings Summary
Kezar Life Sciences Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Kezar Life Sciences Reports First Quarter 2023 Financial Results
Kezar Life Sciences Inc reports results for the quarter ended in March - Earnings Summary
Kezar Life Sciences Inc expected to post a loss of 29 cents a share - Earnings Preview
Kezar Life Sciences Inc reports results for the quarter ended in December - Earnings Summary
U.S. RESEARCH ROUNDUP-Freeport-Mcmoran, Harley-Davidson, Varonis Systems
Brief: Kezar Life Sciences Reports Q4 And Year End 2022 Financial Results And Provides Business Update
Kezar Life Sciences Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Kezar Life Sciences Presents Positive Complete Results From Mid-Stage Trial In Lupus Nephritis
Brief: Kezar Life Sciences Reports Third Quarter 2022 Financial Results, Provides Business Update
Kezar Life Sciences Inc reports results for the quarter ended in September - Earnings Summary
Kezar Life Sciences Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Kezar Life Sciences To Present Complete Results From The Phase 2 Mission Trial Of Zetomipzomib In Patients With Lupus Nephritis
Kezar gains on FDA nod to test autoimmune hepatitis drug in humans
Brief: Kezar Receives FDA Clearance Of Zetomipzomib IND For Treatment Of Autoimmune Hepatitis